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 ABSTRACT    
Continuing with the efforts to identify new active compounds against malaria and  leishmaniasis, fourteen new 3-amino-
1,4-di-N-oxide quinoxaline-2-carbonitrile derivatives were synthesized and evaluated for their in vitro antimalarial and 
antileishmanial activity against Plasmodium falciparum Colombian FCR-3 strain and Leishmania amazonensis strain 
MHOM/BR/76/LTB-012A. Further computational studies to analyze graphic SAR and ADME properties were 
undertaken. Results indicate that compounds with one halogenous group substituted in position 6 and 7 provide an 
efficient approach for further development of antimalarial and antileishmanial agents. In addition, interesting ADME 
properties were found 
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 Malaria is by far the world’s most important tropical parasitic disease and one of the oldest diseases known to mankind. 
For nearly half a century, chloroquine (CQ) has been the primary therapy of choice but today CQ-resistant Plasmodium 
falciparum is observed in nearly all of the malaria-endemic regions, being the cause of the most deadly form of malaria 
[1]. Mortality, currently estimated at over a million people per year, has risen in recent years, probably due to increasing 
resistance. Therefore, it is necessary to develop cheaper and more effective drugs against the parasite [2,3]. Leishmaniasis 
is generally recognized for its cutaneous form which causes non-fatal disfiguring lesions, although epidemics of the 
potentially fatal visceral form cause thousands of deaths. Today this disease threatens about 350 million people and 12 
million people are believed to be currently infected, with about 1–2 million estimated new cases occurring every year. 
Most available drugs against Leishmaniasis are costly, require long treatment regimes and are becoming more and more 
ineffective, necessitating the discovery of new drugs [4]. Moreover since the introduction of miltefosine at the beginning 
of this century, no new antileishmanial compounds have been approved for human treatment [5]. 
     Many classes of organic compounds have been tested to achieve this aim, with special attention being paid to nitrogen 
heterocycles, five- and six-membered rings. Quinoxalines display diverse pharmacological activities as antibacterial, 
antiviral, anticancer and antiparasitic agents and more specifically, their 1,4-di-N-oxides, which increase the biological 
properties enormously [6]. As a result of our research project, several papers have been published, in which both synthesis 
and biological activity assessments have been described for a large number of quinoxaline and quinoxaline 1,4-di-N-oxide 
derivatives with a variety of substituents in positions 2, 3, 6 and 7 of the quinoxaline ring, as the introduction of a 
carbonitrile group in position 2, which increases the antiparasitic activity, and an amine group in position 3, with the aim 
of linking new molecules with interesting activities [7-10]. We synthesized and evaluated in vitro fourteen new 3-amino-
1,4-di-N-oxide quinoxaline-2-carbonitrile analogues against Plasmodium falciparum Colombian FCR-3 strain and 
Leishmania amazonensis MHOM/BR/76/LTB-012A strain. The ADME properties of all molecules were calculated in 
silico. 
     We have prepared fourteen new quinoxaline 1,4-di-N-oxide derivatives. The benzofuroxane starting compounds (BFX, 
I, Scheme 1-2) have been prepared using previously described methods [11,12]. The 3-amino-1,4-di-N-oxide quinoxaline-
2-carbonitrile derivatives (cyanoamines, II) were obtained by the Beirut reaction from the corresponding BFX with 
malononitrile using N,N-dimethylformamide (DMF) as solvent and triethylamine as catalyst [13]. 
     With regard to scheme 1, the next stage consists of reacting 3-amino-1,4-di-N-oxide quinoxaline-2-carbonitrile 
derivatives with aromatic sulfonyl chloride derivatives in order to synthesize sulfonamides which have shown interesting 
antileishmanial activity [14]. 
     These quinoxaline derivatives were tested for their activity against two parasites: Plasmodium falciparum (responsible 
for malaria) and Leishmania amazonensis (responsible for cutaneous New World leishmaniasis), and against non-
tumorigenic cell line (Murine Peritoneal Macrophages: MPM). Biological activities and graphical representation of the 
structure-activity relationship for series 1 and 2 are presented in Table 1, Table 2 and figure 1 (a,b). None of the 
sulfonamides (compounds 1-7) showed interesting activity against malaria parasite, being 60 - >80 times less active than 
chloroquine. Similarly, most of acetoxybenzamides were scarcely active, being 90 - >100 times less active than 
chloroquine. Only compounds 9 and 14 showed some activity, with an IC50 of approximately 10 µM (although they were 
almost 30 times less active than CQ). Interestingly, a Cl (9) or a F (14) in R7 position increased the activity 4-7 times when 
compared to an H or a CH3 in the same position. As shown in figure 1(b), the position of one electronegative atom (F, Cl 
or O), represented as a blue field, is clearly important in order for the atoms to act as possible hydrogen bond acceptors. 
This contrasts with the groups CH3 and H, which projected hydrophobic regions (represented as golden fields).  
     Compound  9 with an acetoxybenzamide in position 3 is almost twice as active than compound 4, the most active 
compound of the first series. From a spatial point of view, according to figure 1 (a,b), this could mean that a strong 
concentration of electronegative atoms (potential hydrogen bond acceptors) in one same plane is a good feature for 
acetoxybenzamides. Consequently, we can say that the o-nitrophenyl, p-nitrophenyl and 2-naphtyl sulfonamides lower the 
activity. The most active compound against malaria was compound 14 (IC50 7,4 µM), followed by compound 9 (10.8 µM).  
     Against Leishmania, compounds 4 and 5 inhibited 50% of parasite growth at approximately 3 µM, being almost 10-15 
times less active than the reference drug amphotericin B. As we mentioned before, to be active the R7 position must be 
occupied by one electronegative atom Cl, because when missing (7), the activity drops dramatically (86 µM). The 
paranitrophenyl substituent is also responsible for the activity in association with Cl in R7 position, since once it is charged 
by a naphtyl group (1), the activity lowers ten times. Interestingly, the presence of withdrawing groups, such as o-nitro and 
p-nitro, in the sulfonamide region is correlated to the activity (see figure 1b). Nevertheless, compounds 4 and 5 showed a 
low Selectivity Index (2-4), almost ten times lower than the SI of amphotericin B. Although compound 2 and 6 were 
almost 5 times less active than compounds 4 and 5, we decided to test them against Leishmania-infected macrophages, 
because these products were not toxic against non-infected macrophages (> 245 and 89 µM respectively). 
      In infected macrophages, compound 2 was 7 times more active than 6 and showed the best Selectivity Index (>15), 
being very close to that of amphotericin B. In the second series, the most active compound against Leishmania (14) was 2-
3 times less active than compounds 4 and 5. It appears that to be leishmanicidal, the R7 position must be occupied by a 
CH3 or a F. The activity drops when Cl or CH3O are in R
7 position. Nevertheless, when the active compounds were tested 
on non-infected macrophage, they showed some toxicity, being almost as toxic on macrophage as on Leishmania. 
     A computational study designed to predict the ADME properties of our salicylamide and sulfonamide derivatives of 
quinoxaline was performed (results are presented in Table 3). Topological polar surface area (TPSA) is a good indicator of 
drug absorption in the intestines, Caco-2 monolayer penetration, and blood–brain barrier crossing [15]. TPSA was used to 
calculate the percentage of absorption (%ABS) following the equation: %ABS = 109 - 0.345 x TPSA, as reported [16]. In 
addition, the number of rotable bonds (n-ROTB), and Lipinski’s rule of five were also calculated [17]. The most active 
compounds found for antileishmanial and antimalarial bioassays  (compounds 4, 5, 9 and 14) showed medium percentages 
of intestinal absorption, with mean values of 58%, and an excellent n-ROTB, ranging only from 3 to 4 [18]. None of these 
compounds violated any of the Lipinski’s parameters, an important characteristic for future drug-development. 
     On the other hand, correlations between molecular descriptors such as molecular weight, LogP  and activities of 
acetoxybenzamides and sulfonamides derivatives were found. Simple Pearson correlation values, which are useful for 
measuring the association between two variables, were calculated between biological activities reported in Table 1 and 
Table 2, and physical chemical properties in Table 3. In contrast to previously reported results [8,9], whose derivatives 
only correlate between LogP and activities, in our case, an important element for the activity was also conferred by MW of 
the derivatives, an important parameter that is directly related with the size of the molecule, which is useful to illustrate the 
influence of the shape and structural features of a molecule. In the second series, the reported values showed a correlation 
between MW and antimalarial activity and antileishmanial activity respectively, expressed as Log (1/IC50), in which 
higher values indicate exponentially greater potency (the logarithm of inverse of the IC50 is classically used in QSAR 
studies). Compounds in the second series followed a positive linear relationship (r = 0.47 for Malaria, r = 0.64 for 
Leishmania and undetermined for cytotoxicity in murine peritoneal macrophages) while the first series only followed a 
negative linear relationship between LogP and antimalarial activity (r = -0.56), also expressed as Log (1/IC50). 
      
     The seven new sulfonamides presented in this paper were prepared through the synthetic route illustrated in Scheme 1. 
 
 
Scheme 1. General synthesis of sulfonamides. Reagents and conditions: i) malononitrile, DMF, 
triethylamine, 15-90%; ii) pyridine, 0º C, 13-15%. 
 
 
     With regard to Scheme 2, the final synthetic route consists in combining 3-amino-1,4-di-N-oxide 
quinoxaline-2-carbonitrile derivatives with o-acetylsalicyloyl chloride, used for the treatment of infections 




Scheme 2. General synthesis of acetoxybenzamides. Reagents and conditions: i) malononitrile, DMF, 
triethylamine, 15-90%; ii) dry THF, 25%. 
 
     In the last stage of synthesis of sulfonamides, the temperature is critical and it has to stay below 0ºC, 
whereas the last stage of synthesis of acetoxybenzamides is carried out at room temperature. Besides, there is a 
loss of yield due to the purification by column chromatography, decreasing from 50% to 25% 
(acetoxybenzamides) and 13-15% (sulfonamides). 
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CC50  Mø 
(µM)e 
SIf 
1 426.6 H Cl 2-naphtyl >23.4 >78 20 ± 1.4 100 88.6 ± 5.6 4.4 
2 406.1 H CH3 2-naphtyl >24.6 >82 16.3 ± 0.8 81.5 >245.6 > 15.1 
3 420.1 CH3 CH3 2-naphtyl >23.8 >79 >100
 >100 NT NT 
4 421.6 H Cl o-nitrophenyl 17.4 ± 0.5 58 3.1 ± 0.1 15.5 6.8 ± 0.8 2.2 
5 421.6 H Cl p-nitrophenyl >23.7 >79 2.1 ± 0.1 10.5 7.9 ± 0.3 3.8 
6 456.1 Cl Cl p-nitrophenyl 18.7 ± 1 62 15.9 ± 1.3 -15 89.1 ± 6.4 5.6 
7 387.1 H H p-nitrophenyl 20 ± 2 67 86.3 ± 8.5 430 NT - 
CQ 320    0.2 ± 0.1 1 20 ± 1.4 100 88.6 ± 5.6 4.4 
Anf B 320      0.2 1 4.4 22 
a IC50 against P. falciparum FCR-3.  
b CQ Index: IC50 drug/ IC50 CQ. 
c IC50 against axenic amastigotes of L. amazonensis.  
d Anf Index: IC50 of compounds /IC50 amphotericin B. 
e Cytotoxicity in murine peritoneal macrophages.  
Selectivity Index (SI): CC50 drug/ IC50 drug.  
MW molecular weight; NT: Not tested. 















CC50  Mø 
(µM)e 
SIf 
8 364 H H 41.4 ± 1.1 138 111.8 ± 3.2 559 NT - 
9 398.5 H Cl 10.8 ± 1.8 36 33.6 ± 1.3 168 NT - 
10 378 H CH3 52.8 ± 1.4 176 18.8 ± 0.3 94 21.7 ± 1.9 1.1 
11 394 H CH3O 27 ± 1.7 90 42.4 ± 1.7 212 NT - 
12 400 F F 36 ± 0.9 120 14.8 ± 0.1 74 10.5 ± 0.7 0.7 
13 392 CH3 CH3 59.4 ± 2.0 198 17.6 ± 0.6 88 12.5 ± 1.1 0.7 
14 382 H F 7.4 ± 0.6 25 7.3 ± 0.1 36.5 13.6 ± 1.6 1.8 
CQ 320   0.3 ± 0.01 1     
Anf B      0.2 ± 0.01 1 4.4 ± 0.1 22 
a IC50 against P. falciparum FCR-3.  
b CQ Index: IC50 drug/ IC50 CQ. 
c IC50 against axenic amastigotes of L. amazonensis.  
d Anf Index: IC50 of compounds /IC50 amphotericin B. 
e Cytotoxicity in murine peritoneal macrophages.  
Selectivity Index (SI): CC50 drug/ IC50 drug.  
MW molecular weight; NT: Not tested. 
 
 


















rule  ≤140  <500 <5  ≤5 ≤10 ≤1 
1 67.28 120.9 3 426.84 1.19 0.65 1 8 0 
2 67.27 120.8 3 406.42 0.96 0.43 1 8 0 
3 67.27 120.8 3 420.45 1.34 0.80 1 8 0 
4 51.48 166.7 4 421.79 -0.08 0.65 1 11 1 
5 51.48 166.7 4 421.79 -0.03 0.65 1 11 1 
6 51.48 166.7 4 456.22 0.57 1.25 1 11 1 
7 51.48 166.7 4 387.33 -0.68 0 1 11 1 
8 69.98 113.1 4 364.32 -0.47 0 1 9 0 
9 64.11 130.1 4 398.76 0.18 0.65 1 9 0 
10 64.11 130.1 4 378.34 -0.04 0.43 1 9 0 
11 60.94 139.3 5 394.34 -0.43 0.04 1 10 0 
12 64.11 130.1 4 400.29 -0.23 0.24 1 9 0 
13 64.11 130.1 4 392.37 0.33 0.80 1 9 0 
14 64.11 130.1 4 396.33 -0.33 0.14 1 9 0 
a %ABS, percentage of absorption, calculated by: %ABS = 109 – (0.345 x TPSA); TPSA, topological polar surface area; n-RT, 
number of rotable bonds; miLogP , logarithm of compounds partition coefficient between n-octanol and water.  
bHydrophilic-lipophilic fragments determined  for changes in R7 and R
6, calculated by the sum of  Σπ values,  using as reference the 




     A computational study for prediction of ADME properties of all molecules was performed using 
Molinspiration online property calculation toolkit (MolinspirationCheminformatics). Parameters such as 
solubility (miLogP), Topological Polar Surface Area (TPSA) [15], and absorption (%ABS) using the formula: 
%ABS = 109 – (0.345 x TPSA) [16] were calculated. Violations of Lipinski’s rule-of-five were evaluated [17]. 
     Analysis of structure-activity relationship was performed using Cresset’s field technology 
(http://www.cresset-group.com/) which condenses the molecular fields down to a set of points around the 
molecule, termed “Field Points” [25]. Field Points are the local extrema of the electrostatic, van der Waals and 
hydrophobic potentials of the molecule. Throughout FielView® software, the Field Points are colored as 
follows: Blue; negative field points (like to interact with positives/H-bond donors on a protein), red; positive 
field points (like to interact with negatives/H-bond acceptors on a protein), yellow; van der Waals surface field 
points (describing possible surface/vdW interactions), gold/orange; Hydrophobic field points (describe regions 
with high polarizability/hydrophobicity).  
     Quinoxaline derivatives harboring a halogenous group in positions 6 and 7 present interesting activity 
against Plasmodium and Leishmania parasite and show interesting in silico ADME characteristics. These 
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